ES2645959T3 - Péptidos basados en lactoferrina humana que tienen actividad antiinflamatoria - Google Patents
Péptidos basados en lactoferrina humana que tienen actividad antiinflamatoria Download PDFInfo
- Publication number
- ES2645959T3 ES2645959T3 ES12700715.1T ES12700715T ES2645959T3 ES 2645959 T3 ES2645959 T3 ES 2645959T3 ES 12700715 T ES12700715 T ES 12700715T ES 2645959 T3 ES2645959 T3 ES 2645959T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- peptide
- peptides
- infections
- wounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 161
- 102000004196 processed proteins & peptides Human genes 0.000 title description 45
- 230000003110 anti-inflammatory effect Effects 0.000 title description 8
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 title 1
- 102000050459 human LTF Human genes 0.000 title 1
- 206010052428 Wound Diseases 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 16
- 230000000845 anti-microbial effect Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 238000011282 treatment Methods 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 9
- 239000006161 blood agar Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000007621 bhi medium Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010041925 Staphylococcal infections Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940126601 medicinal product Drugs 0.000 description 5
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 208000014912 Central Nervous System Infections Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000025222 central nervous system infectious disease Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003641 microbiacidal effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000588626 Acinetobacter baumannii Species 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000035874 Excoriation Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010021531 Impetigo Diseases 0.000 description 2
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 2
- 206010050031 Muscle strain Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000031650 Surgical Wound Infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000007382 columbia agar Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002515 Animal bite Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000032840 Catheter-Related Infections Diseases 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 101100422881 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) swf-1 gene Proteins 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- IUPKBWSKNCAQJQ-JYYYXURSSA-N kisspeptin 234 Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(C)=O)C)C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 IUPKBWSKNCAQJQ-JYYYXURSSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940100686 otic ointment Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010026901 peptide 106 Proteins 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 206010034878 phimosis Diseases 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152213A EP2481751A1 (en) | 2011-01-26 | 2011-01-26 | Human lactoferrin derived peptides |
| EP11152213 | 2011-01-26 | ||
| PCT/EP2012/051111 WO2012101156A2 (en) | 2011-01-26 | 2012-01-25 | New synthetic peptides and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2645959T3 true ES2645959T3 (es) | 2017-12-11 |
Family
ID=44123487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12700715.1T Active ES2645959T3 (es) | 2011-01-26 | 2012-01-25 | Péptidos basados en lactoferrina humana que tienen actividad antiinflamatoria |
| ES12701866.1T Active ES2633353T3 (es) | 2011-01-26 | 2012-01-25 | Péptidos derivados de lactoferrina humana y su uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12701866.1T Active ES2633353T3 (es) | 2011-01-26 | 2012-01-25 | Péptidos derivados de lactoferrina humana y su uso |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9132165B2 (enExample) |
| EP (3) | EP2481751A1 (enExample) |
| JP (2) | JP6158713B2 (enExample) |
| KR (2) | KR101933900B1 (enExample) |
| CN (2) | CN103476792B (enExample) |
| AU (2) | AU2012210564B2 (enExample) |
| BR (2) | BR112013018264A2 (enExample) |
| CA (2) | CA2825246A1 (enExample) |
| ES (2) | ES2645959T3 (enExample) |
| MX (2) | MX342313B (enExample) |
| PL (1) | PL2668205T3 (enExample) |
| RU (2) | RU2593757C2 (enExample) |
| WO (2) | WO2012101156A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
| GB201401877D0 (en) * | 2014-02-04 | 2014-03-19 | Univ Tromsoe | Peptides |
| CN104888202A (zh) * | 2014-05-22 | 2015-09-09 | 闫牧乔 | 一种治疗扁桃体炎的药物 |
| IT201800002457A1 (it) * | 2018-02-07 | 2019-08-07 | Neilos S R L | Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie |
| RU2681216C1 (ru) * | 2018-09-05 | 2019-03-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ стимуляции регенерации инфицированных ран кожи и мягких тканей с применением пептида Gly-His-Lys-D-Ala |
| RU2681310C1 (ru) * | 2018-09-05 | 2019-03-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ первичной хирургической обработки инфицированных ран кожи и мягких тканей с использованием пептида Gly-His-Lys-D-Ala |
| US12295990B2 (en) | 2018-11-09 | 2025-05-13 | The Wistar Institute Of Anatomy And Biology | Use of lactoferrin for generating myeloid-derived suppressor cells |
| KR102032945B1 (ko) * | 2018-12-03 | 2019-10-16 | 순천대학교 산학협력단 | 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물 |
| NL2024839B1 (en) * | 2020-02-05 | 2021-09-13 | Cbmr Scient Nanoscience B V | Antimicrobial peptide for treatment and controlling skin disorders relating to microbial infection |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2818056B2 (ja) | 1990-09-07 | 1998-10-30 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
| US5656591A (en) | 1992-01-23 | 1997-08-12 | Morinaga Milk Industry Co., Ltd. | Antimicrobial agents and method for treating products therewith |
| JP3347819B2 (ja) | 1993-06-28 | 2002-11-20 | 森永乳業株式会社 | 抗菌性ペプチドの精製方法 |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| JP3529423B2 (ja) | 1994-04-01 | 2004-05-24 | 森永乳業株式会社 | 抗菌性ペプチドの製造方法 |
| JP3812957B2 (ja) | 1994-08-02 | 2006-08-23 | 森永乳業株式会社 | 角膜損傷治療剤 |
| JPH08143468A (ja) | 1994-11-17 | 1996-06-04 | Morinaga Milk Ind Co Ltd | 抗潰瘍剤 |
| JP2001504447A (ja) | 1996-08-12 | 2001-04-03 | エイプラス サイエンス インベスト アーベー | ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防 |
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| SE9804614A0 (en) | 1998-07-06 | 2000-01-07 | A+ Science Invest Ab | New peptides and use thereof |
| US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
| AU5010800A (en) * | 1999-05-14 | 2000-12-05 | Regents Of The University Of California, The | Anti-inflammatory therapy for inflammatory mediated infection |
| CA2388910C (en) | 1999-11-11 | 2008-10-07 | Am-Pharma B.V. | Antimicrobial activity of the first cationic cluster of human lactoferrin |
| RU2165769C1 (ru) * | 2000-07-13 | 2001-04-27 | Якубовская Раиса Ивановна | Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения |
| SE0102067D0 (sv) | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| US7183381B2 (en) | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
| ES2532392T3 (es) * | 2006-07-10 | 2015-03-26 | Pba3 Biomed Gmbh | Péptidos antimicrobianos |
| JP5384948B2 (ja) * | 2007-02-09 | 2014-01-08 | ジェノミディア株式会社 | 新規ポリペプチド及びそれを有効成分として含有する抗菌剤 |
| JP5444544B2 (ja) * | 2007-02-09 | 2014-03-19 | ジェノミディア株式会社 | 血管新生誘導剤及びそれに用いられるポリペプチド |
| EP2050461A1 (en) | 2007-10-19 | 2009-04-22 | PharmaSurgics in Sweden AB | Peptides based on the sequence of human lactoferrin and their use |
| EP2060586A1 (en) | 2007-11-14 | 2009-05-20 | PharmaSurgics in Sweden AB | New synthetic arginine substituted peptides and their use |
| BRPI0904622A2 (pt) * | 2008-05-23 | 2016-06-21 | Asubio Pharma Co Ltd | peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma |
| EP2387390B1 (en) * | 2009-01-13 | 2012-11-28 | PharmaSurgics in Sweden AB | Hylauronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation |
| EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
| KR101341210B1 (ko) * | 2013-01-24 | 2013-12-12 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 신규한 항균 펩타이드 및 이의 용도 |
-
2011
- 2011-01-26 EP EP11152213A patent/EP2481751A1/en not_active Withdrawn
-
2012
- 2012-01-25 EP EP12701866.1A patent/EP2668205B1/en not_active Not-in-force
- 2012-01-25 KR KR1020137021856A patent/KR101933900B1/ko not_active Expired - Fee Related
- 2012-01-25 BR BR112013018264A patent/BR112013018264A2/pt not_active IP Right Cessation
- 2012-01-25 PL PL12701866T patent/PL2668205T3/pl unknown
- 2012-01-25 KR KR1020137021855A patent/KR101949210B1/ko not_active Expired - Fee Related
- 2012-01-25 CA CA2825246A patent/CA2825246A1/en not_active Abandoned
- 2012-01-25 RU RU2013139302/04A patent/RU2593757C2/ru active
- 2012-01-25 RU RU2013139294/10A patent/RU2596393C2/ru active
- 2012-01-25 AU AU2012210564A patent/AU2012210564B2/en not_active Ceased
- 2012-01-25 US US13/981,609 patent/US9132165B2/en not_active Expired - Fee Related
- 2012-01-25 BR BR112013018365A patent/BR112013018365A2/pt not_active IP Right Cessation
- 2012-01-25 US US13/981,614 patent/US8846608B2/en active Active
- 2012-01-25 ES ES12700715.1T patent/ES2645959T3/es active Active
- 2012-01-25 CN CN201280006521.7A patent/CN103476792B/zh not_active Expired - Fee Related
- 2012-01-25 WO PCT/EP2012/051111 patent/WO2012101156A2/en not_active Ceased
- 2012-01-25 JP JP2013550865A patent/JP6158713B2/ja not_active Expired - Fee Related
- 2012-01-25 MX MX2013008530A patent/MX342313B/es active IP Right Grant
- 2012-01-25 CN CN201280006526.XA patent/CN103459419B/zh not_active Expired - Fee Related
- 2012-01-25 ES ES12701866.1T patent/ES2633353T3/es active Active
- 2012-01-25 CA CA2825247A patent/CA2825247A1/en not_active Abandoned
- 2012-01-25 EP EP12700715.1A patent/EP2668204B1/en not_active Not-in-force
- 2012-01-25 WO PCT/EP2012/051112 patent/WO2012101157A1/en not_active Ceased
- 2012-01-25 AU AU2012210565A patent/AU2012210565B2/en not_active Expired - Fee Related
- 2012-01-25 MX MX2013007995A patent/MX341020B/es active IP Right Grant
- 2012-01-25 JP JP2013550864A patent/JP6158712B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2645959T3 (es) | Péptidos basados en lactoferrina humana que tienen actividad antiinflamatoria | |
| Méndez-Samperio | The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections | |
| ES2384195T3 (es) | Agonistas de PPAR-gamma para la inducción de la expresión de péptidos antimicrobianos catiónicos como estimulantes inmunoprotectores | |
| ES2847388T3 (es) | Composiciones y métodos para desestabilizar, alterar y dispersar biopelículas | |
| JP6157514B2 (ja) | 抗菌性ペプチド | |
| CN110078794B (zh) | 一种抗菌肽及其应用 | |
| AU2012210565A1 (en) | Human lactoferrin derived peptides and there use | |
| AU2012210564A1 (en) | Human lactoferrin based peptides having antiinflammatory activity | |
| US8815812B2 (en) | Synthetic arginine substituted peptides and their use | |
| JP2022517764A (ja) | 治療または予防に使用するためのディフェンシン断片 | |
| CN111320678A (zh) | 抗菌肽突变体及其应用 | |
| WO2015027071A1 (en) | Gpr81 agonists and methods thereof for promoting production of secretory iga | |
| RU2705989C1 (ru) | Применение низкоразмерных двумерных (2D) складчатых структур оксигидроксида алюминия (ALOOH) для преодоления устойчивости бактерий к антибиотикам | |
| JP2002161041A (ja) | 感染症治療剤 |